secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001285550-24-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%
--------------------------------------------------------------------------------

- Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.
- Capital equipment sales surged 255% to $1.4M; SmartFrame OR received 510(k) clearance and first clinical cases performed.
- Activated 8 new hospital sites in Q1, a company record, bringing total active sites to over 80.
- Operational cash burn reduced 32% to $3.8M; cash and equivalents totaled $35.4M after $16.2M public offering.
- Reaffirmed FY2024 revenue outlook of $28M-$32M; first-ever neuro gene therapy BLA submitted by partner PTC Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/0001285550-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/clpt-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001285550-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer